Colin completed his undergraduate degree in Physiology and Zoology from the University of Sheffield, (UK) and his Ph.D. through the University of Hull (UK) on the ultrasonic assessment of bone in the department of applied physics, while employed as a research assistant to an orthopedic surgeon. Following his Ph.D., Colin worked at Syntex Pharmaceuticals (now part of Roche) and Procter & Gamble Pharmaceuticals before moving to the USA in 1994 to start a new company, Bona Fide Ltd. which was sold to Bio-Imaging Technologies (now Bioclinica) 5 years later. He was instrumental in supporting the growth of BioClinica from 35 people to over 1800 employees. As Vice President and later Senior Vice President Medical Affairs, for a publicly traded company, he headed up sales for nearly 5 years, marketing for 7 years and scientific/medical/regulatory oversight of the company for 12 years. This also included handling regulatory affairs and supporting clients with their communication with the FDA. In the last year at Bioclinica, he was heading up strategic development.
Colin resigned from Bioclinica in 2015 and joined Alacrita as a consultant (and also started his own analytics company, BrackenData and Bracken Marketing). He has been involved in supporting clients obtain marketing approval for numerous drugs/biologic’s and several devices across a range of therapeutic areas, including oncology, but specifically at the intersect of imaging and clinical trials.
Colin has been providing medical and scientific consulting for over 25 years for the biopharmaceutical and device companies through Bioclinica, Bona Fide Ltd and now Alacrita. He has been an advisor on several safety boards and Ad-com’s. He has become a recognized expert in the field of osteoarthritis for the biopharmaceutical industry and also in the use of novel analgesic medications and the safety effect on joints (anti-Nerve Growth Factors or aNGF’s). He has presented at the FDA on several occasions and attended meetings in the development of the guidance documents, including Imaging in Clinical Trials and discussions on Progression Free Survival in oncology.
Since mid-2016, Colin’s consulting has been primarily focused on the area of nuclear medicine, both with a novel PET diagnostic but also the strategic development of a peptide receptor radionuclide therapy (PRRT). He is also providing strategic development for the regulatory pathway for a novel imaging companion diagnostic and FDA interaction.
Colin has over 70 peer-reviewed publications and has published 3 books through Springer, the latest entitled “Medical Imaging in Clinical Trials” in 2014. He has 3 patents, all of which led to marketed products. He is a fellow of both the Institute of Clinical Research and the Institute Physics and Engineering in Medicine and is a Chartered Scientist.
When not working, Colin has a keen interest in aviation, holding a current pilots license. He also cycles and enjoys kayaking, photography, and travel when time allows.